Leslie Williams, ImmusanT CEO [File photo]
Arch-backed ImmusanT scraps PhII as celiac therapy flops in a key test
Arch helped provide ImmunsanT a $40 million round back in 2017 so it could afford a Phase II study for their lead therapy to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
